

**REMARKS**

This Amendment is filed with a Request for Continued Examination (R.C.E.) in the above-identified application.

In summary, a Notice of Allowance was previously issued June 2, 2009 in the above-identified application, allowing claims 21-24 and 26 as previously presented.

In the present amendment, claims 1-20, 24 and 25 are cancelled, claims 21-23 and 26 were previously of record and new claims 27 to 42 are added in the above-identified application. Claim 22 has been amended to be an independent claim. Amended claim 26 is directed solely to a method of treatment of coronary artery disease and new claim 28 is directed to a method of treatment of atherosclerosis, each of which, respectively, comprise administering a therapeutically effective amount of a compound of claim 21. New claims 27 to 42 are directly based on subject matter as presented in previously allowed claims 21, 22 and 24 and in the originally filed disclosure. Claim 24 has been cancelled in favor of new claims 27 to 39, which incorporate the subject matter of cancelled claim 24.

Applicants' Attorney, Grace C. Hsu, wishes to thank Examiner Mark L. Berch for the August 20, 2009 telephonic discussion regarding addition of the subject matter of newly added claims directed to treatment methods.

Support for all amendments are found in the originally filed specification and claims. No new matter has been added to the claims or specification by amendment.

Applicants also reserve the right to file non-elected inventions as the subject of future applications, which may derive priority from the present application, without prejudice.

Applicants request consideration and entry into the record of the above and amendments and remarks.

**Information Disclosure Statement / PTO 1449 Forms**

Applicants respectfully submit herewith an Information Disclosure Statement under 37 C.F.R. 1.97 (b)(4), a corresponding U.S. PTO 1449 Form and references cited therein for consideration by the U.S.P.T.O.

Applicants further note that WO 02/068420, which is cited in the accompanying U.S. PTO 1449 Form, is in the German language. A CAS English language abstract corresponding to WO 02/068420 is listed on the form PTO-1449 and submitted herewith. In addition, Applicants note that U.S. Patent Appln. Pub. Nos. US 2004/077645 and US

U. S. Serial No.: 10/589,474  
Group Art Unit No.: 1624

2006/205711, each of which have been cited in the accompanying U.S.P.T.O. 1449 Form, are related to WO 02/068420.

Applicants respectfully request that the Examiner please review the above-identified documents and if in accordance with U.S. Patent Practice, initial and return copies of the attached U.S.P.T.O. 1449 form.

### **CONCLUSION**

In view of the above, entry and consideration of this Amendment is respectfully requested.

If any additional fees or charges are required, authorization is hereby granted to charge any necessary fees to Deposit Account No. 19-2570 accordingly.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned attorney at the number below.

Respectfully submitted,



---

Grace C. Hsu  
Attorney for Applicant  
Registration No. 51,336

GLAXOSMITHKLINE  
Corporate Intellectual Property  
UW2220 - P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone: (610) 270-4650  
Fax: (610) 270-5090

*N:\GCH\APPS\PB 60727 RCE CASES\PB60727 RCE\Amendment.doc*